112 stories
GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
An NPR investigation found fewer than 1 in 4 patients stay on GLP-1 medications after a year, with most planning to restart later. Researchers warn that up to 40% of weight lost on GLP-1s is lean muscle, and cycling on and off the drugs may accelerate sarcopenia. When patients stop, fat regains rapidly while muscle recovery is uncertain.
A study of 220,043 patients published in Diabetes, Obesity and Metabolism found that combining GLP-1 receptor agonists with SGLT2 inhibitors reduced all-cause mortality by 29%, the cardiovascular composite outcome by 19%, and heart failure risk by 22% compared to SGLT2 inhibitor use alone over 1.3 years of median follow-up.
Mechanistic data from the REMODEL trial presented at the 2026 World Congress of Nephrology showed semaglutide decreased renal fat, lowered arterial resistance, and stabilized cortical fibrosis. Biopsies revealed reduced immune cells around glomeruli, and transcriptomic analysis identified glomerular endothelial cells as the most responsive cell type to treatment.
The FDA published updated guidance clarifying compounding requirements now that semaglutide and tirzepatide shortages have been resolved. The statement reaffirmed enforcement deadlines for 503A and 503B pharmacies while acknowledging ongoing legal challenges from the Outsourcing Facilities Association.
A comprehensive review by D.J. Drucker in Nature Medicine outlines GLP-1 medicines expanding beyond diabetes and obesity into cardiovascular disease, neurodegenerative disorders, substance use, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease. New multi-agonist molecules with optimized pharmacokinetics are producing greater weight loss.
The Week reports that India's GLP-1 market is surging following semaglutide patent expiry in March, with doctors warning that self-medication — particularly through unapproved online channels — poses serious risks including pancreatitis and thyroid complications. Experts emphasize the need for clinical oversight and proper dose titration.
A Mass General Brigham study of over 90,000 HFpEF patients published in JAMA found semaglutide reduced heart failure hospitalization or all-cause mortality by 42%, while tirzepatide achieved a 58% risk reduction compared with sitagliptin. Both drugs showed acceptable safety profiles with benefits appearing early in treatment.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Stanford researchers found approximately 10% of people may have resistance to GLP-1 drugs, limiting effectiveness for glucose regulation and weight loss. The study examined individual variation in how GLP-1 drugs slow gastric emptying.
The Atlantic examines how GLP-1 pills are reshaping obesity treatment. The shift from weekly injections to daily pills addresses a major compliance barrier, though patients must continue therapy indefinitely.
Eli Lilly formally launched Foundayo (orforglipron) eight days after FDA approval, having pre-stocked $1.5 billion worth of the drug. The oral obesity market now features a direct Lilly vs Novo Nordisk competition.
The FDA is intensifying enforcement against compounding pharmacies selling unapproved GLP-1 products, threatening seizure and injunction. Hims & Hers was specifically named following the February 2026 TrumpRx launch.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.
A new review highlights GLP-1 RAs achieving a 55% reduction in apnea-hypopnea index and 14.9% mean weight loss in non-diabetic populations, with pleiotropic effects across cardiovascular, renal, and skeletal systems.
A large GWAS study published in Nature identified a missense variant in GLP1R predicting an additional 0.76 kg of weight loss per allele copy. GIPR variation was linked to nausea/vomiting side effects specific to tirzepatide users.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.